General
Preferred name
GNE-272
Synonyms
P&D ID
PD103119
CAS
1936428-93-1
Tags
available
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION GNE-272 is a potent and selective CBP/EP300 inhibitor with IC50 values of 0.02, 0.03 and 13 ¦ÌM for CBP, EP300 and BRD4, respectively. GNE-272 is also a selective in vivo probe for CBP/EP300[1].
DESCRIPTION GNE-272 is a potent and selective CBP/EP300 inhibitor with IC50s of 0.02, 0.03, 0.41 and 13 μM for CBP, EP300, BRET and BRD4, respectively. It shows significant antiproliferative effects in hematologic cancer cell lines and modulates MYC expression in vivo, corresponding to antitumor activity in AML tumor models. It is also a selective in vivo probe for the Bromodomains of CBP/EP300. (BOC Sciences Bioactive Compounds)
Compound Sets
5
BOC Sciences Bioactive Compounds
gne-272-cas-1936428-93-1-item-7144
EU-OPENSCREEN Bioactive Compound Library
EOS100049
Mcule NIBR MoA Box Subset
MCULE-6257997568
MedChem Express Bioactive Compound Library
HY-100726
Novartis Chemogenetic Library (NIBR MoA Box)
External IDs
11
Properties
(calculated by RDKit )
Molecular Weight
424.2
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
3
cLogP
3.03
TPSA
77.21
Fraction CSP3
0.41
Chiral centers
1.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Member status
member
MOA
N-Ac Lysine competitive CREBBP/EP300 inhibitor
Pathway
Epigenetics
Solubility
Soluble in DMSO
Target
Epigenetic Reader Domain
Histone Acetyltransferase
Source data